In elderly aged related macular degeneration (AMD) is the common eye disease which impairs the vision and most of the time it creates permanent vision loss. Because elderly population constitute the larger percentage among society, visual loss due to AMD has become a growing problem. Despite the advances made in developing therapeutics, there is still no satisfactory treatment. The limitations of the available treatments are due to the absence of potent, non-invasive therapy. Furthermore, part of the available drugs targets angiogenesis and create a hypoxic environment that augment further angiogenesis. Therefore, it is reasonable to consider eye integrity and the correlation between hypoxia and angiogenesis before developing successful drugs. This review highlighted issues regarding the available therapeutic strategies and explored whether AMD can be managed by employing specific nanoformulations.

在老年人中，黄斑变性（AMD）是常见的眼部疾病，会损害视力，并且在大多数情况下会造成永久性视力丧失。由于老年人口在社会中所占比例较高，因此，AMD造成的视力丧失已成为一个日益严重的问题。尽管在开发治疗剂方面取得了进步，但是仍然没有令人满意的治疗方法。现有治疗方法的局限性是由于缺乏有效的，非侵入性的治疗方法。此外，部分可用药物靶向血管生成并创建缺氧环境，从而进一步促进血管生成。因此，在开发成功的药物之前，有必要考虑眼睛的完整性以及缺氧与血管生成之间的相关性。